MedCity News December 3, 2020
The contracts are complicated and full of risks for drug companies. But there’s also a risk to steering clear of the arrangements — reduced or restricted access to a company’s medication.
Prescription drugs are on their way to eating up the biggest slice of Puerto Rico’s $3.4 billion Medicaid budget. To head off rising costs, the island turned to what is still a relatively new trend in the pharmaceutical world — value-based contracting.
At its most basic level, a value-based contract emphasizes the quality of care rather than the quantity. In the case of pharmaceutical firms, it means tying reimbursement not just to how many pills patients take but also to whether patients get better. The risk is that they...
Today's Sponsors
Today's Sponsor